SEATTLE, April 3, 2008 /PRNewswire/ -- A policy comment in Science today quotes Genelex out of context:
"Some Web sites make explicit claims about the utility of CYP450 testing for particular drugs, such as the claim by Genelex that pharmacogenetic testing is "required to effectively prescribe Paxil" (http://www.healthanddna.com/professional/paxil.html).
The actual statement is:
Paxil (paroxetine) is metabolized through CYP2D6. Pharmacogenetic
testing of this pathway serves as an anchor for the intense personalization
required to effectively prescribe Paxil and other antidepressant medicines.
Facts and quotes:
-- "The cytochrome P-450 test represents a major advance in the ability
to provide the best care possible for depression."
-- Hospitalized psychiatric patients who are poor metabolizers cost
$4,000 - $6,000 more in medical care compared to patients with an
average metabolizer genotype. Virtually, all antidepressants and
antipsychotic medicines are processed by enzymes with a high
incidence of poor metabolizers. Journal of Clinical
Psycopharmacology 20:246 2000.
-- Fifty-nine percent of drugs most commonly cited in ADR studies are
processed by enzymes with genes known to have poor metabolizer
variants. This is compared to 7% of a random selection of the top
selling drugs. (JAMA 286:2270 2001).
-- Multiple studies have found that people with CYP variants require
lower doses of the affected medications. Molecular Psychiatry
-- "Putting what we know into practice would prevent more disease than
|SOURCE Genelex Corporation|
Copyright©2008 PR Newswire.
All rights reserved